14.05.2013 • News

Aesica Enters Research Collaboration with University of Nottingham

Aesica, the global contract manufacturing organisation (CMO), announces a partnership with the University of Nottingham for the commercial development of alternative methods in amide bond synthesis. This latest partnership is already the Aesica Innovation Board's (AIB) fourth with an academic institution in less than six months; having been established to help bridge the growing R&D gap by identifying early stage technologies for development into commercial applications.

Amide bond formation is fundamental in pharmaceutical manufacturing. A recent survey conducted by the Green Chemistry Institute Roundtable identified that amide bond formation was utilised in 84 % of a set of drug candidates. The partnership's aim is to revolutionize traditional amide formation techniques by generating alternative methods for amide bond formation, which will be more eco-friendly and chemically versatile. This innovative approach will be commercially available to Aesica customers in the next two to three months and already the company is actively seeking commercial opportunities to work with potential compounds that could benefit from this novel technology.

This collaboration builds upon recently announced plans to establish a Centre of Excellence for Sustainable Chemistry, part-funded by an investment from the Higher Education Funding Council for England (HEFCE) UK Research Partnership Investment Fund.

 

Special Issue

Circular Plastics Economy
Explore the Future of Plastics

Circular Plastics Economy

This special CHEManager issue explores the industry’s pivotal shift towards a more sustainable, circular plastics value chain. Readers will find expert analysis and real-world solutions for today’s most pressing recycling and regulatory challenges.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read

Photo

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.